<DOC>
	<DOCNO>NCT00096265</DOCNO>
	<brief_summary>This randomized phase III trial study whole-brain radiation therapy stereotactic radiosurgery without temozolomide erlotinib see well work compare whole-brain radiation therapy stereotactic radiosurgery treat patient brain metastasis secondary non-small cell lung cancer . Radiation therapy use high-energy x-ray kill tumor cell . Stereotactic radiosurgery may able deliver x-ray directly tumor cause less damage normal tissue . Drugs use chemotherapy , temozolomide , work different way stop tumor cell divide stop grow die . Erlotinib may stop growth tumor cell block enzymes necessary growth block blood flow tumor . It yet know whether radiation therapy stereotactic radiosurgery effective without temozolomide erlotinib treat brain metastasis .</brief_summary>
	<brief_title>Radiation Therapy Stereotactic Radiosurgery With Without Temozolomide Erlotinib Treating Patients With Brain Metastases Secondary Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare survival patient non-small cell lung cancer brain metastasis treat whole brain radiotherapy stereotactic radiosurgery v without temozolomide erlotinib . SECONDARY OBJECTIVES : I . Compare time CNS progression patient treat regimen . II . Compare quality-adjusted survival patient treat regimen . III . Compare 3-month quality life patient treat regimen . IV . Compare 6-month performance status patient treat regimen . V. Compare 6-month steroid dependence patient treat regimen . VI . Compare cause death ( neurologic v ) patient treat regimen . VII . Determine effect non-protocol chemotherapy patient . OUTLINE : This randomize , multicenter study . Patients stratify accord age presence extracranial metastasis ( &lt; 65 year old AND extracranial metastasis vs ≥ 65 year old OR extracranial metastasis ) , number metastasis ( 1 vs 2 3 ) , extent extracranial disease ( none v present ) . Patients randomize 1 3 treatment arm . ARM I : Patients undergo whole brain radiotherapy ( WBRT ) daily day 1-5 , 8-12 , 15-19 . Within 14 day completion WBRT , patient undergo stereotactic radiosurgery . ARM II : Patients undergo WBRT stereotactic radiosurgery arm I . Beginning first day WBRT , patient receive oral temozolomide daily day 1-21 . Beginning 4 week completion WBRT , patient may receive oral temozolomide alone daily day 1-5 . Treatment temozolomide repeat every 28 day 6 course absence disease progression unacceptable toxicity . ARM III : Patients undergo WBRT stereotactic radiosurgery arm I . Beginning first day WBRT , patient receive oral erlotinib daily 6 month . In arm , patient recurrent brain metastasis may undergo additional stereotactic radiosurgery . Quality life assess baseline 3 , 6 , 9 , 12 , 18 , 24 month . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer One 3 intraparenchymal brain metastasis contrastenhanced MRI , meet follow criterion : Well circumscribe tumor ( ) Maximum diameter ≤ 4.0 cm If multiple lesion present one lesion maximum diameter , lesion must ≤ 3.0 cm maximum diameter No metastasis within 10 mm optic apparatus portion optic nerve chiasm would include highdose stereotactic radiosurgery boost field No metastases brainstem , midbrain , pons , medulla No prior complete resection know brain metastasis Subtotal resection allow provide residual disease ≤ 4.0 cm maximum diameter No clinical radiographic evidence progression ( study lesion [ ] ) within past month Patients brain metastases initial presentation require 1 month scan document stable disease Stable extracranial metastasis allow No know preexisting liver metastases No leptomeningeal metastasis MRI cerebrospinal fluid evaluation Synchronous brain metastasis initial diagnosis allow Performance status Zubrod 01 Hemoglobin ≥ 8 g/dL Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 AST &lt; 2 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2 time ULN unless due elevate bone metastasis Total bilirubin normal Lactic dehydrogenase &lt; 2 time ULN Creatinine &lt; 1.5 time ULN No clinically active interstitial lung disease Chronic stable asymptomatic radiographic change allow Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative Neurologic function status 02 No major medical illness psychiatric impairment would preclude study participation No history allergic reaction attribute compound similar chemical biologic composition erlotinib temozolomide No concurrent immunotherapy No concurrent biologic therapy , exclude growth factor epoetin alfa No prior temozolomide erlotinib No concurrent chemotherapy study radiotherapy Other concurrent chemotherapy allow study radiotherapy , except follow : Temozolomide erlotinib ( arm I ) Erlotinib ( arm II ) Temozolomide ( arm III ) No prior cranial radiotherapy No concurrent intensitymodulated radiotherapy Concurrent radiotherapy painful bone lesion allow No concurrent radiotherapy 15 % bone marrow No concurrent therapy brain metastasis unless recurrence detect More 30 day since prior investigational drug No concurrent enzymeinducing antiepileptic drug include , limited , follow ( patient randomize receive erlotinib ) : Phenytoin Carbamazepine Rifampin Phenobarbital Primidone Oxcarbazepine No concurrent investigational drug No concurrent Hypericum perforatum ( St. John 's wort ) No drug alter gastric pH ( e.g. , proton pump inhibitor H2 antagonist ) within 4 hour erlotinib administration ( arm III patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>